Details

Autor(en) / Beteiligte

• Diaz-Menindez, Maximiliano
• Sullivan, Megan M.
• Butendieck, Ronald R.
• Abril, Andy
• Majithia, Vikas
• Wang, Benjamin
• Berianu, Florentina

Titel

Diffuse alveolar hemorrhage secondary to sarcoidosis

Ist Teil von

• Clinical rheumatology, 2023-06, Vol.42 (6), p.1701-1704

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2023

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Diffuse alveolar hemorrhage (DAH) is a pulmonary condition that can be caused by autoimmune disorders such as lupus, small vessel vasculitis, and antiphospholipid syndrome. Sarcoidosis as a cause of DAH has been reported; however, the literature remains limited. We performed a chart review for patients with a diagnosis of both sarcoidosis and DAH. Seven patients met inclusion criteria. Mean (range) patient age was 54 years (39–72), and 3 patients had a history of tobacco use. Diagnosis of DAH and sarcoidosis were concurrent for 3 patients. Corticosteroids were used for treatment of DAH in all patients; 2 (including 1 with refractory DAH) were successfully treated with rituximab. We believe sarcoidosis-associated DAH is more common than previously reported. It is essential to consider sarcoidosis in the differential diagnosis of immune-mediated DAH. Key Points • Sarcoidosis can cause diffuse alveolar hemorrhage (DAH); more extensive studies are needed to estimate this condition’s prevalence. • BMI of 25 or higher appears to be a risk factor for the development of sarcoidosis-associated DAH.